Amgen Inc. and AstraZeneca PLC have reported positive Phase 3 results for TEZSPIRE, or tezepelumab, in eosinophilic esophagitis, with the biologic meeting both co-primary endpoints and all key secondary endpoints in the CROSSING study. The companies said improvements in histologic remission and dysphagia were statistically significant and clinically meaningful at week 24 and remained evident through week 52, strengthening the case for expanding TEZSPIRE beyond its currently approved respiratory indications.
The announcement is potentially important because eosinophilic esophagitis requires success on two fronts that do not always move together: reducing the underlying eosinophilic inflammation visible in esophageal tissue and improving the swallowing problems that patients actually experience. CROSSING achieved both objectives, although Amgen and AstraZeneca have so far released only top-line findings and have not disclosed the detailed response percentages, magnitude of dysphagia improvement or subgroup data that will be needed to judge how TEZSPIRE compares with existing options.
What did the TEZSPIRE CROSSING Phase 3 trial measure?
CROSSING enrolled 368 patients aged 12 to 80 years with symptomatic and histologically active eosinophilic esophagitis. Participants were randomized in a 1:1:1 ratio to receive one of two TEZSPIRE doses or placebo by subcutaneous administration every four weeks while remaining on maintenance therapy.
The first co-primary endpoint examined histologic remission at week 24, defined as a peak esophageal eosinophil count of six or fewer cells per high-power microscopic field. For context, a count of 15 or more eosinophils per high-power field is commonly used as part of the histological threshold for diagnosing eosinophilic esophagitis.
The second co-primary endpoint addressed the frequency and severity of difficulty swallowing through changes in the patient-reported Dysphagia Symptom Questionnaire. This dual structure matters because an experimental therapy that produces cleaner biopsies without improving the experience of eating would deliver an incomplete clinical benefit.
Amgen and AstraZeneca said both tested doses produced statistically significant and clinically meaningful improvements across the co-primary endpoints at week 24, with benefits sustained through week 52. Key secondary measures included endoscopic disease features, histologic severity and extent, inflammatory remission and total endoscopic remission.
Why is eosinophilic esophagitis difficult to treat?
Eosinophilic esophagitis is a chronic immune-mediated inflammatory disorder in which eosinophils accumulate in the esophagus. Over time, persistent inflammation can contribute to structural changes, narrowing and fibrosis, while patients can experience difficulty swallowing, pain, food becoming stuck and anxiety around meals.
Amgen estimates that more than 470,000 people in the United States have the condition and says prevalence has increased five-fold since 2009. The company also reports that nearly half of patients, including adolescents, fail to achieve adequate disease control with first-line approaches such as dietary restriction, proton-pump inhibitors and swallowed topical corticosteroids.
This treatment gap explains why biologic therapy has become important in eosinophilic esophagitis. Rather than broadly suppressing inflammation, biologics can interrupt selected immune signals thought to drive the disease, potentially creating more durable control in patients who remain symptomatic despite conventional approaches.
The challenge is that EoE is not simply a laboratory abnormality. Patients can adapt their eating behavior by cutting food into small pieces, avoiding certain textures or drinking unusually large amounts of liquid with meals, which can make symptom burden less obvious unless clinicians ask specifically about behavioral compensation.
How does TEZSPIRE’s TSLP mechanism differ from downstream inflammatory targeting?
TEZSPIRE is a monoclonal antibody directed against thymic stromal lymphopoietin, or TSLP, an epithelial cytokine positioned relatively early in inflammatory signaling. Blocking TSLP is intended to interrupt several downstream inflammatory pathways rather than neutralizing only one later mediator.
That upstream position has already supported TEZSPIRE’s use in severe asthma, and the drug is also approved in the United States as an add-on maintenance treatment for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal polyps.
Positive EoE results now give Amgen and AstraZeneca efficacy evidence across a third epithelial-driven inflammatory disease. The scientific attraction is that epithelial tissues are not passive barriers; they can actively initiate immune responses when exposed to allergens, injury or other triggers. TSLP represents one of the signaling molecules connecting that epithelial activation with downstream immune cells.
If the full CROSSING dataset confirms robust benefit across symptoms, histology and endoscopic measures, TEZSPIRE could strengthen the pharmaceutical case for targeting upstream epithelial alarm signals across multiple diseases rather than developing a completely separate biological strategy for each organ.
Does TEZSPIRE already have enough evidence for an EoE approval?
Not yet. Positive Phase 3 top-line results provide the central efficacy signal, but Amgen and AstraZeneca still need to disclose the full dataset and submit the relevant evidence to regulatory authorities. The companies said detailed results will be presented at a future medical meeting and shared with regulators.
Several details will matter. Investors, clinicians and regulators will want to see actual remission rates, the magnitude of Dysphagia Symptom Questionnaire improvement, results at both tested doses, discontinuations, adverse events and whether efficacy remains consistent across adolescents and adults.
The safety statement is encouraging but similarly high-level. Amgen said the safety profile in CROSSING was generally consistent with TEZSPIRE’s approved indications. Existing prescribing information includes precautions relating to hypersensitivity, parasitic infection and live attenuated vaccines, while postmarketing anaphylaxis has been reported.
The absence of a new top-line safety signal removes one obvious obstacle, but comparative positioning cannot be assessed until the complete data are available.
Could every-four-week dosing become a competitive advantage?
Treatment burden is particularly relevant in chronic diseases where patients may remain on therapy for years. CROSSING evaluated TEZSPIRE every four weeks, a schedule that could become an attractive feature if efficacy proves competitive with other advanced therapies.
Dosing frequency alone will not determine adoption. Physicians will weigh depth of histologic remission, symptom response, durability, safety, age eligibility, insurance coverage and the presence of other inflammatory diseases that might make one biologic more attractive than another.
TEZSPIRE could nevertheless benefit from familiarity. Allergists, pulmonologists and other specialists already use the drug in severe asthma, potentially reducing some of the practical barriers associated with introducing an entirely new biological mechanism.
The opportunity may be especially interesting in patients whose disease crosses organ systems. A therapy capable of controlling more than one TSLP-driven condition could eventually simplify treatment for selected patients, although that proposition would require indication-specific approvals and clinical evidence.
What should the pharmaceutical industry watch next?
The first event is the presentation of detailed CROSSING data. The distinction between a statistically significant trial and a commercially differentiated therapy often becomes visible only when absolute response rates and treatment effects can be compared with established standards.
The second is regulatory timing. Amgen and AstraZeneca have not yet announced an EoE submission date in the top-line release, so the pathway from positive Phase 3 data to potential label expansion remains to be defined.
The larger scientific question extends beyond EoE. TEZSPIRE is increasingly becoming a test of whether TSLP can function as a broadly useful upstream target across diseases arising from epithelial immune dysregulation. Success in asthma provided the first major validation, chronic rhinosinusitis with nasal polyps added another, and CROSSING now extends the signal to the esophagus.
That trajectory does not mean every epithelial inflammatory disease will respond to TSLP blockade. It does, however, change the development question facing Amgen and AstraZeneca. TEZSPIRE may no longer be viewed primarily as an asthma biologic searching for additional indications; it is increasingly becoming a platform drug whose ultimate value will depend on how widely the TSLP mechanism travels.
